Cookeville attorney’s start-up accepted into the Altitude Lab biotech incubator
QUANTiSCOPE was launched in late 2022 through the federal Biomedical Advanced Research and Development Authority (BARDA) DRIVe program.
A start-up founded by Cookeville attorney Kevin Christopher has been accepted into the Altitude Lab biotech incubator in Salt Lake City.
Named QUANTiSCOPETM, the company was launched in late 2022 through the federal Biomedical Advanced Research and Development Authority (BARDA) DRIVe program. QUANTiSCOPE uses artificial intelligence (AI) computer vision technology to decode high-content biological imaging and enhance decision-making in applications such as preclinical drug discovery.
The company also recently joined the Microsoft for Startups Founders Hub to optimize the launch of its initial enterprise applications on the Azure platform and is working through industry pilots in 2023. Christopher will present QUANTiSCOPE on a larger scale on September 20 as part of the MIT Startup Exchange Demo Day through the MIT Industrial Liaison Program.
“Quantiscope PBC democratizes advanced image analysis and phenotypic modeling for drug discovery researchers, accelerating rare disease solutions, empowering under-resourced communities, and bolstering U.S. biodefense through innovative SaaS (Software-as-a-Service) tools,” Christopher explains. “We integrate AI/ML (machine learning) imaging analysis seamlessly into therapeutic pipelines, streamlining hit identification, enhancing optimization, extending patents, and ultimately driving life-saving innovations.”
The start-up’s cloud-based phenotypIQTM solution offers researchers plug-and-play access to cutting-edge AI-driven image analysis, simplifying data interpretation and decision-making. Through its phenotypic modeling dashboard, QUANTiSCOPE guides the selection of the most promising preclinical candidates, ensuring both efficacy and safety.